Associations - PALB2 mutation

PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ipilimumab + niraparib Sensitive: C3 – Early Trials ASCO 2022 - 3 days (NewC3)	ipilimumab + niraparib Sensitive: C3 – Early Trials ASCO 2022 - 3 days - (New C3)
PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline	cisplatin + gemcitabine Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline	talazoparib Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	rucaparib Sensitive: A2 - Guideline	rucaparib Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	Ovarian Cancer Ovarian Cancer	PALB2 mutation PALB2 mutation	Ovarian Cancer Ovarian Cancer	olaparib Sensitive: B - Late Trials	olaparib Sensitive: B - Late Trials
PALB2 mutation PALB2 mutation	Breast Cancer Breast Cancer	PALB2 mutation PALB2 mutation	Breast Cancer Breast Cancer	CX-5461 Sensitive: B - Late Trials	CX-5461 Sensitive: B - Late Trials
PALB2 mutation PALB2 mutation	Ovarian Cancer Ovarian Cancer	PALB2 mutation PALB2 mutation	Ovarian Cancer Ovarian Cancer	CX-5461 Sensitive: B - Late Trials	CX-5461 Sensitive: B - Late Trials
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria	ABT-888 Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	rucaparib Sensitive: C2 – Inclusion Criteria	rucaparib Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Breast Cancer Breast Cancer	PALB2 mutation PALB2 mutation	Breast Cancer Breast Cancer	olaparib Sensitive: C2 – Inclusion Criteria	olaparib Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Urothelial Cancer Urothelial Cancer	PALB2 mutation PALB2 mutation	Urothelial Cancer Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria	olaparib Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials	everolimus Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PALB2 mutation PALB2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials	lenvatinib Resistant: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	oxaliplatin Sensitive: C3 – Early Trials	oxaliplatin Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials	PARP inhibitor Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials	cisplatin + gemcitabine Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Endometrial Cancer Endometrial Cancer	PALB2 mutation PALB2 mutation	Endometrial Cancer Endometrial Cancer	rucaparib + E 3810 Sensitive: C4 – Case Studies	rucaparib + E 3810 Sensitive: C4 – Case Studies
PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin + docetaxel Sensitive: D – Preclinical	carboplatin + docetaxel Sensitive: D – Preclinical